Supporter and Exhibitor Opportunities
NCCN Guidelines and Compendium Updated
Flash Update Sent June 27, 2012
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer. These NCCN Guidelines® are currently available as Version 1.2013.
- Small Cell Lung Cancer (SCLC)
- For patients with clinical stage T1-2, N0 disease, the following footnotes were added: "Pathologic mediastinal staging is not required if the patient is not a candidate for surgical resection or if non-surgical treatment is pursued." "Select patients may be treated with chemotherapy/RT as an alternative to surgical resection."
- "Primary Progressive Disease" was added to Relapse and now has the same treatment recommendations. Performance status was added after "Relapse or primary progressive disease". For patients with performance status (PS) 0-2, a category 1 designation was added to subsequent chemotherapy.
- In the Principles of Chemotherapy section, temozolomide 75 mg/m2/day x 21 days was added to relapse ‹ 2-3 mo and relapse › 2-3 mo up to 6 mo.
- Principles of Radiation Therapy extensively revised and updated (especially prophylactic brain irradiation [PCI]), including the addition of a section for brain metastases.
- Principles of Supportive Care was revised:
- "Conivaptan and tolvaptan" were added as treatment options for select patients with the syndrome of inappropriate antidiuretic hormone (SIADH).
- "Metyrapone" was added as a treatment option for select patients with Cushing's syndrome in whom ketoconazole is not effective.
- Lung Neuroendocrine Tumors (LNTs)
- "Cisplatin/etoposide ± RT" was added as a primary treatment option for select patients with stage IIIB disease.
- "Consider octreotide (including long-acting release [LAR])" was added as a primary treatment option for select patients with stage IIIB or IV disease.
For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.